HHS Nominee Vows To Tackle High Drug Costs, Despite His Ties To Industry
Alex M. Azar II, the former president of the U.S. division of Eli Lilly, says the U.S. drug system encourages price increases — but he intends to work on that problem.
Cost and Quality
1,001-1,020 of 3,363 results
-
-
Despite Prod By ACA, Tax-Exempt Hospitals Slow To Expand Community Benefits
The Affordable Care Act mandated that hospitals exempt from taxes work to provide health benefits to the community. But a study finds that has been slow to get off the ground.
-
Running On Empty: CHIP Funding Could Run Out Jan. 19 For Some States
A fiscal patch that Congress approved last month proves not enough to keep coverage for children afloat, CMS says.
-
Readers Have Bones To Pick, From Health System Flaws To Covering Pot Beat
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
-
Maine Voters Chose Medicaid Expansion. Why Is Their Governor Resisting?
Even though voters in Maine decided to expand Medicaid through a ballot measure, the law's fate is still unclear. Gov. Paul LePage says the Legislature must find funds for it without raising taxes. Advocates say the law is on their side and expansion must be implemented.
By Sarah Varney -
Trump Administration Rule Paves Way For Association Health Plans
Proponents say the proposed regulation will give some consumers more affordable insurance options. Critics warn that the coverage could be less comprehensive.
-
Care Suffers As More Nursing Homes Feed Money Into Corporate Webs
Increasingly, owners of nursing homes outsource services to companies in which they also have financial interest or control. That allows the nursing homes to claim to be in the red while owners reap hidden profits.
By Jordan Rau -
Children’s Insurance, Other Health Programs Funded — For Now — In Bill
In a short-term spending bill, Congress extends money to the Children’s Health Insurance Program through March.
By Julie Rovner -
FDA Chief Says He’s Open To Rethinking Incentives On Orphan Drugs
The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
-
Arthritis Drugs Show How U.S. Drug Prices Defy Economics
Drugs that treat rheumatoid arthritis started out costing about $10,000 a year. Ten years later, they list for more than $40,000.
-
Infection Lapses Rampant In Nursing Homes But Punishment Is Rare
A Kaiser Health News analysis of federal inspection records shows that nursing home inspectors labeled mistakes in infection control as serious for only 161 of the 12,056 homes they have cited since 2014.
By Jordan Rau -
Bonus Tucked Into GOP Tax Bill For Those Aiming To Deduct Medical Expenses
The House sought to eliminate the tax deduction, generally used by people with serious illnesses or those who need long-term care services but it was eventually restored in the final bill — and expanded.
-
Biosimilars, Biologics And New Legal Challenges For RA Treatments
As biosimilar products reach the market and rival more established RA treatments, the players are exploring legal challenges involving antitrust and anti-competitive behavior.
-
-
Arizona Declares Opioid Emergency, But Signals Are Mixed Over Best Response
Arizona is one of a few states that have declared the opioid epidemic a public health emergency. There's no uniformity in what that means from state to state, though, and even within Arizona, there's a wide divergence of opinion on how best to tackle the problem.
-
When Nursing Homes Push Out Poor And Disabled Patients
Complaints are rising in California and other states about improper evictions and discharges. Advocates say some patients end up in cheap hotels, homeless or back in the hospital.
-
Doing More Harm Than Good? Epidemic of Screening Burdens Nation’s Older Patients
Patients are often aggressively screened for cancer, even if they won’t live long enough to benefit.
By Liz Szabo -
Drug Industry Spent Millions To Squelch Talk About High Drug Prices
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.
By Jay Hancock -
Canada’s Single-Payer Health System: What Is True? What Is False?
It’s a regular part of the politically charged debate over health care. But the lines sometimes blur between rhetoric and how Canada’s system actually works.
-
Looking North: Can A Single-Payer Health System Work In The U.S.?
American single-payer advocates want to emulate Canada’s system. But many Canadian experts say the U.S. first needs to address some basic questions.